Teriparatide biosimilar - Intas Pharmaceuticals

Drug Profile

Teriparatide biosimilar - Intas Pharmaceuticals

Alternative Names: Parathyroid hormone - Intas Pharmaceuticals; PTH - Intas Pharmaceuticals; Terifrac

Latest Information Update: 07 Sep 2016

Price : $50

At a glance

  • Originator Intas Pharmaceuticals
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteoporosis
  • Phase III Fracture

Most Recent Events

  • 21 Oct 2013 Biomarkers information updated
  • 31 Dec 2011 Launched for Osteoporosis in India (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top